CUV - Bullish ReversalCUV is forming bullish divergence and also breakout the previous lower high. it may reverse from its current trend.
Next report date
Report period
H2 2024
EPS estimate
0.28EUR
Revenue estimate
34.69 MEUR
0.375EUR
18.69 MEUR
47.82 MEUR
40.13 M
About CLINUVEL PHARMACEUTICALS LIMITED
Sector
CEO
Philippe Jacques Wolgen
Headquarters
Melbourne
Website
Founded
1999
ISIN
AU000000CUV3
FIGI
BBG000C0XJ25
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.
Clinuvel (CUV) set up for the next 200-350% run-up!Chart pattern:
Since 2014 a regular chart-pattern can be observed in the Clinuvel ( CUV ) chart. After one year of a strong run-up (mostly starting in late February), the stock reaches a local peak (around Sept-Nov) and starts a correction (around -35% to -50%), followed by a longer sideways conso
CUV - Long Term OpportunitiesI am optimistic about the long term view of CUL. Technical indicators are supporting long term fundamentals.
Clinuvel passt it's regressionHey everyone,
I think Clinuvel passt through it's regression and is now on it's way to get back upwards.
My first goal is the Resistance zone so i'm gonna set my TP at 24.25$.
RSI and my Histogram also show to buy.
Much fun with that trade!
Leave a follow :)
CUV: ASX - CLINUVEL PHARMACEUTICALSFrom September 2018 through to May 2019 this stock was in a re-accumulation phase. You can see there was a sell off in September when supply it the market and the stock pulled back.
From November the stock hit support and from there we started making higher lows. We took at the top of the trading r
Short CUVOn the weekly the MACD is bearish with the Stoch doing the same thing, it needs break below $25.61 for a start of a bearish trend. On the Daily, the chart shows that the stock has rally to the 13 ema with the confirmation on the stoch as a bearish move for a breakout. Looking for shorts below $24.61
Short CUVOn the daily it had a nice rally into the 13 and 20 EMA with a downward trend on the 50 EMA, also the stoch confirm bearish movement as well. On the weekly, it is up trending, but if it goes past $24.61 it might be a start of a bearish run. Will keep this on the watch list, looking to short below $2
CUV set to reach new highsOBV and Volume increasing reflecting stronger buying interest. Strong fundamentals and awaiting news from FDA as well!
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange CLINUVEL PHARMACEUTICALS stocks are traded under the ticker UR9.
CLINUVEL PHARMACEUTICALS is going to release the next earnings report on Aug 28, 2024. Keep track of upcoming events with our Earnings Calendar.
UR9 earnings for the last quarter are 0.23 EUR per share, whereas the estimation was 0.22 EUR resulting in a 2.80% surprise. The estimated earnings for the next quarter are 0.16 EUR per share. See more details about CLINUVEL PHARMACEUTICALS earnings.
CLINUVEL PHARMACEUTICALS revenue for the last quarter amounts to 29.92 M EUR despite the estimated figure of 30.38 M EUR. In the next quarter revenue is expected to reach 21.46 M EUR.
Yes, you can track CLINUVEL PHARMACEUTICALS financials in yearly and quarterly reports right on TradingView.
UR9 net income for the last quarter is 6.75 M EUR, while the quarter before that showed 11.73 M EUR of net income which accounts for −42.51% change. Track more CLINUVEL PHARMACEUTICALS financial stats to get the full picture.
Yes, UR9 dividends are paid annually. The last dividend per share was 0.03 EUR. As of today, Dividend Yield (TTM)% is 0.33%. Tracking CLINUVEL PHARMACEUTICALS dividends might help you take more informed decisions.
CLINUVEL PHARMACEUTICALS dividend yield was 0.28% in 2023, and payout ratio reached 8.07%. The year before the numbers were 0.27% and 9.47% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, UR9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CLINUVEL PHARMACEUTICALS stock right from TradingView charts — choose your broker and connect to your account.
We've gathered analysts' opinions on CLINUVEL PHARMACEUTICALS future price: according to them, UR9 price has a max estimate of 28.04 EUR and a min estimate of 9.69 EUR. Read a more detailed CLINUVEL PHARMACEUTICALS forecast: see what analysts think of CLINUVEL PHARMACEUTICALS and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CLINUVEL PHARMACEUTICALS EBITDA is 24.83 M EUR, and current EBITDA margin is 53.24%. See more stats in CLINUVEL PHARMACEUTICALS financial statements.